Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


12 Items
Title  Creator  Group name  Publishing year 
Genomics to select treatment for patients with metastatic breast cancer Andre et al. EquipeCTCS 2022-10
Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population De Laurentiis et al. EquipeCTCS 2022-01
Outcome beyond third-line chemotherapy for metastatic triple-negative breast cancer in the French ESME program Cabel et al. EquipeCTCS 2021-04
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population De Laurentiis et al. EquipeCTCS 2021-10
Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial Bachelot et al. EquipeCTCS 2021-02
Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort Frank et al. EquipePC Aug 2020
UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroup D'Hondt et al. EquipePC Oct 18, 2019
Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program Jacot et al. EquipeCTCS May 14, 2019
Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort Darlix et al. EquipeCTCS Dec 2019
[Breast cancer screening: On our way to the future] Delaloge et al. EquipeCTCS 09 2016
Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis Lefebvre et al. EquipeELC Dec 2016
Coexpression of androgen receptor and FOXA1 in nonmetastatic triple-negative breast cancer: ancillary study from PACS08 trial Guiu et al. EquipeELC 2015
12 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés